Abbott Laboratoriesvs.Bio-Rad Laboratories
ABT vs BIO · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Abbott Laboratories is about 20× larger than Bio-Rad Laboratories by market cap; Abbott Laboratories trades at the lower P/E (35.5 vs 43.5); year to date, Bio-Rad Laboratories leads (+26.0% vs −6.9%).
Side by side
| ABT | BIO | |
|---|---|---|
| Market cap | $193B | $9.7B |
| Price | $116.13 | $390.34 |
| Today | −0.5% | +2.2% |
| Return YTD | −6.9% | +26.0% |
| Return 1Y | −12.0% | +25.7% |
| P/E | 35.5 | 43.5 |
| P/S | 4.1 | 3.7 |
| P/B | 3.8 | 1.3 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Abbott LaboratoriesABT
In vitro diagnostics, medical devices that include the Libre glucose sensors, nutrition products and generic medicines: Abbott runs all four.
Full ABT profile →Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →More ABT & BIO comparisons
Other head-to-heads in the Diagnostics segment.